Trial Profile
Does Modulating the Gut Hormones, Incretins, Modify Vascular Function, Thereby Reducing the Risk of Vascular Complications in Insulin Resistant Individuals?
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Vildagliptin (Primary)
- Indications Insulin resistance
- Focus Pharmacodynamics
- 24 Apr 2017 Status changed from recruiting to completed.
- 17 May 2010 New trial record